NTRA · Natera, Inc.
$403.95
+0.64% last session
End-of-day data · close of 2026-10-23
Market cap
$58B
Enterprise value
$57B
Trailing P/E
—
Forward P/E
-2,271.4
Dividend yield
0.0%
Beta
1.50
Avg volume
1M
Employees
6K
Daily Change %
0.64%
5 Days Change
2.02%
10 Days Change
1.44%
30 Days Change
2.71%
60 Days Change
22.47%
Month to Day Change
-1.74%
Year to Day Change
75.20%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NTRA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
JP Morgan
Overweight$460
+13.9% vs priceMorgan Stanley
Overweight$435
+7.7% vs priceBarclays
Overweight$475
+17.6% vs priceCitigroup
Buy$480
+18.8% vs priceRBC Capital
Outperform$460
+13.9% vs priceUBS
Buy$435
+7.7% vs priceWells Fargo
Equal-Weight$284
-29.7% vs priceGoldman Sachs
Neutral$245
-39.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Maintains | Buy | $375 → $500 |
| 2026-10-14 | JP Morgan | Maintains | Overweight | $360 → $460 |
| 2026-10-13 | Morgan Stanley | Maintains | Overweight | $355 → $435 |
| 2026-10-13 | TD Cowen | Maintains | Buy | $340 → $480 |
| 2026-10-07 | Barclays | Maintains | Overweight | $340 → $475 |
| 2026-10-06 | Citigroup | Maintains | Buy | $365 → $480 |
| 2026-10-01 | Guggenheim | Maintains | Buy | $360 → $475 |
| 2026-09-25 | RBC Capital | Maintains | Outperform | $350 → $460 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 10.1% above the 50-day MA ($366.97).
- bullish: Price vs 200-day MA: Trading 54.4% above the 200-day MA ($261.62).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-2.61) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($182.65) and high ($425.64).
NTRA Price Chart
Loading chart for NTRA…
Fundamentals
About Natera, Inc.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
MTD
Mettler-Toledo International, I
$33B 20.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.